Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tanruprubart · ANX-005

Monoclonal antibody · Antagonist of complement C5 (C5) · developed by Annexon

Phase 3 Most advanced trial

ANNX Developer

2 Registered trials

What is Tanruprubart?

Tanruprubart (ANX005) is an antibody administered intravenously. It is studied in Guillain-Barré syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ANX-005
Drug type: Monoclonal antibody
Targets: complement C5 (C5)
Mechanism: Antagonist of complement C5 (C5)
Pathways: complement activation
Therapy area: Neurology
Developer: Annexon, Inc. (ANNX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: N5WBB45U8L

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07020819	Phase 3	Guillain-Barre Syndrome	Recruiting	ANNX
NCT04701164	Phase 3	Guillain-Barre Syndrome	Completed	ANNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Guillain-Barre Syndrome

Other drugs acting on C5

Cemdisiran Phase 2 Nomacopan Phase 3

More from Annexon

ANX009 Phase 1 ANX105 Phase 1 ANX1502 Phase 1 Vonaprument Phase 3

Sources

ClinicalTrials.gov NCT04701164

Updated Oct 3, 2026. Something wrong or missing? Report it on the ANNX page.

Follow ANNX, the company behind Tanruprubart

See ANNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANNX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z